Fidaxomicin + Vancomycin + Placebo
ApprovedTerminated 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Clostridium Difficile
Conditions
Clostridium Difficile
Trial Timeline
Nov 29, 2012 → Apr 15, 2013
NCT ID
NCT01775397About Fidaxomicin + Vancomycin + Placebo
Fidaxomicin + Vancomycin + Placebo is a approved stage product being developed by Astellas Pharma for Clostridium Difficile. The current trial status is terminated. This product is registered under clinical trial identifier NCT01775397. Target conditions include Clostridium Difficile.
What happened to similar drugs?
7 of 20 similar drugs in Clostridium Difficile were approved
Approved (7) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01775397 | Approved | Terminated |
Competing Products
20 competing products in Clostridium Difficile